Cancers (Basel)

This paper provides a comprehensive overview of the clinical challenges associated with Glioblastoma Multiforme (GBM), the most common and aggressive form of primary brain cancer. Despite standard treatments, GBM remains notoriously difficult to manage, with a very low five-year survival rate.

The paper examines why GBM is so resistant to conventional therapies. It highlights that the standard of care—surgical resection followed by concurrent chemoradiotherapy (using temozolomide) and adjuvant chemotherapy—is frequently undermined by the tumor's biological complexity. The authors detail how the blood-brain barrier (BBB) prevents many therapeutic agents from reaching the tumor site, while the tumor's internal environment actively promotes survival and recurrence.

A significant portion of the paper is dedicated to the biological mechanisms that allow GBM to evade treatment:

• DNA Repair Enzymes: The enzyme MGMT can repair DNA damage caused by chemotherapy, effectively neutralizing the drug's impact.
• Mismatch-Repair (MMR) Deficiency: When DNA repair pathways are dysfunctional, tumor cells can develop resistance to alkylating agents like temozolomide.
• Glioma Initiating Cells (GICs): These stem-like cells possess self-renewal capabilities and are highly resistant to radiation. They utilize "checkpoint kinases" to pause cell division while they repair DNA damage, allowing them to survive radiation therapy.
• ABC Transporters: These transmembrane proteins act as "pumps" that actively efflux chemotherapy drugs out of the cancer cells, preventing the drugs from reaching effective concentrations.
• Hypoxia: The low-oxygen environment within the tumor promotes the growth of GICs and triggers pathways that make the tumor more aggressive and resistant to both radiation and drug therapy.

Understanding these resistance mechanisms is critical for the development of next-generation therapies. The paper emphasizes that while surgical and radiation techniques have become more precise, they are insufficient on their own. The authors suggest that the future of GBM treatment lies in overcoming these specific biological barriers—particularly through the use of nanocarriers—to improve drug delivery across the blood-brain barrier and to sensitize resistant tumor cells to existing treatments.